This site is intended for healthcare professionals
News

CHMP recommends Ozawade for the treatment of excessive daytime sleepiness in obstructive sleep apnoea.- Bioproject Pharma

Read time: 1 mins
Last updated:28th Jun 2021
Published:25th May 2021
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Ozawade (pitolisant), intended for the treatment of excessive daytime sleepiness in obstructive sleep apnoea.
Condition: Sleeping Disorders
Type: drug
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest